Top-News

Nuvation Bio Aktie News

Aktie
WKN:  A2QPAG ISIN:  US67080N1019 US-Symbol:  NUVB Branche:  Biotechnologie Land:  USA
8,29 $
-0,02 $
-0,24%
7,1166 € 16:31:29 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,40 Mrd. €
Streubesitz
14,29%
KGV
-1,57
Index-Zuordnung
-

Nuvation Bio News

08.10.25 - PR Newswire
NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
NYSE Content Advisory: Pre-​Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street PR Newswire
08.10.25 - PR Newswire
NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street
NYSE Content Advisory: Pre-​Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
10.07.25 - PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up PR Newswire
18.02.25 - PR Newswire
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm PR Newswire
15.02.25 - wallstreetONLINE Redaktion
Börsenstar: 1 geheimer Top-Investor & Milliardär, der Warren Buffett Konkurrenz macht
Dieser eher unbekannte Investor hat den S&P-500- und MSCI-​World-Index um Längen geschlagen.Warren Buffett ist in der Investmentwelt sehr bekannt. Ihm gelang es, zwischen ...
20.12.24 - PR Newswire
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »